ASCENTAGE (06855) Company Profile - Company Info, Industry & Management

返回 Overview News Financials Shareholders Profile IPO ›

Industry

Innovative Drugs & Biologics 0.02%

124 stocks in this industry

3 >7%

3 5~7%

10 3~5%

36 0~3%

15 0%

38 0~3%

13 3~5%

1 5~7%

5 >7%

Down 52 Up 57

Industry RankingsValue (HKD)Rank

Revenue (Last FY)673.25M65/112

Net Profit (Last FY)-1.46B120/125

ROE (Last FY)-93.83%105/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition

YANG Dajun Executive Director

WANG Shaomeng Non-Executive Director

LU Simon Dazhong Non-Executive Director

YE Changqing Independent Non-Executive Director

REN Wei Independent Non-Executive Director

David SIDRANSKY Independent Non-Executive Director

Marina S. BOZILENKO Independent Non-Executive Director

Debra YU Independent Non-Executive Director

Marc E. Lippman, MD Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2025-12-30.

About this page

This page shows ASCENTAGE (06855) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

ASCENTAGE 06855

Company Information

Industry

Management

ASCENTAGE 06855·

Company Information

Industry

Management

ASCENTAGE 06855